Skip to main
ALMS
ALMS logo

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis Inc has a robust pipeline with projected peak sales of $2 billion for its drug targeting Systemic Lupus Erythematosus (SLE), highlighting significant revenue potential, albeit with a conservative 20% probability ascribed for approval. The company's emphasis on leveraging its proprietary precision data analytics platform and a team experienced in precision medicine positions it well to navigate the challenges of drug development in autoimmune disorders. Additionally, the viability of ESK-001 for psoriatic arthritis, supported by positive data from a comparable treatment, further enhances the company's growth prospects.

Bears say

Alumis Inc faces significant risks that contribute to a negative outlook on its stock, prominently due to potential delays in advancing its lead candidate, ESK-001, into pivotal trials, which could impede its development timeline. Moreover, the possibility of ESK-001 failing to demonstrate efficacy in critical indications such as psoriasis (PsO) and systemic lupus erythematosus (SLE) represents a substantial hurdle to achieving market approval and subsequent revenue generation. Additional concerns include regulatory delays, competitive pressures within the inflammation and immunology (I&I) sector, and the risk of dilution, all of which could adversely impact shareholder value and undermine market confidence.

Alumis Inc (ALMS) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 6 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.